Charcot-Marie-Tooth disease (CMT) encompasses a group of inherited peripheral neuropathies characterized by progressive muscle weakness and sensory loss, primarily affecting the distal extremities [1]. As the most common inherited neuropathy (prevalence ~1 in 2,500), CMT results from mutations in genes essential for Schwann cell function, myelin maintenance, and axonal integrity. Schwann cells, the myelinating glia of the peripheral nervous system, play a central role in disease pathogenesis, making them critical targets for therapeutic intervention.
| Property | Value |
|---|---|
| Category | Peripheral Nervous System |
| Location | Peripheral nerves (myelinated axons) |
| Cell Type | Myelinating Schwann cells, Non-myelinating Schwann cells |
| Key Genes | PMP22, MPZ, GJB1, GDA, SH3TC2, MFN2, GDAP1 |
| Inheritance | Autosomal dominant (most common), autosomal recessive, X-linked |
| Primary Pathology | Demyelination, axonal degeneration |
Schwann cells are the resident glial cells of the peripheral nervous system, providing essential support for neuronal function [2]:
| Gene | Protein | Inheritance | Notes |
|---|---|---|---|
| PMP22 | Peripheral Myelin Protein 22 | AD | Most common (CMT1A - PMP22 duplication) |
| MPZ | Myelin Protein Zero | AD | Adhesion molecule, dense line formation |
| GJB1 | Connexin-32 | X-linked | Gap junctions in myelin incisures |
| SH3TC2 | SH3 Domain and Tetratricopeptide Repeats 2 | AR | Endocytic recycling |
| NDRG1 | N-myc Downstream Regulated 1 | AR | Cell differentiation |
| Gene | Protein | Inheritance | Notes |
|---|---|---|---|
| MFN2 | Mitofusin-2 | AD | Mitochondrial dynamics |
| GDA | Guanine Deaminase | AR | Purine metabolism |
| GDAP1 | Ganglioside-Induced Differentiation-Associated Protein 1 | AR/AD | Mitochondrial fission |
| AARS | Alanyl-tRNA Synthetase | AD | Protein synthesis |
The primary pathological hallmark of CMT1 is abnormal myelin formation and maintenance [3]:
Secondary axonal loss is a major contributor to clinical disability:
Emerging evidence suggests:
| Strategy | Target | Status |
|---|---|---|
| Antisense oligonucleotides | PMP22 | Preclinical |
| Gene silencing (RNAi) | PMP22 | Preclinical |
| Gene replacement | GJB1 | Preclinical |
| Small molecule correctors | MPZ, PMP22 | Preclinical |
The study of Schwann Cells In Charcot Marie Tooth Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.